Article
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2022
Zhou Qing, Wu Lin, Hu Pei, An Tongtong, Zhou Jianying, Zhang Li, Liu Xiao-Qing, Luo Feng, Zheng Xin, Cheng Ying, Yang Nong, Li Junling, Feng Jifeng, Han Baohui, Song Yong, Wang Kai, Zhang Li, Fang Jian, Zhao Hong, Shu Yongqian, Lin Xiao-Yan, Chen Zhihong, Gan Bin, Xu Wan-Hong, Tang Wei, Zhang Xiaoying, Yang Jin-Ji, Xu Xiao, Wu Yi-Long
Abstract excerpt
PURPOSE: To establish recommended phase II dose (RP2D) in phase I and evaluate safety and efficacy of abivertinib in patients with EGFR Thr790Met point mutation (T790M)-positive(+) non-small cell lung cancer (NSCLC) with disease progression from prior EGFR inhibitors in phase II. PATIENTS AND METHODS: This multicenter, open-label study included 367 adult Chinese patients. Abivertinib at doses of 50 mg twice a day...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.